sábado, 14 de febrero de 2015

Ahead of Print -Risk Factors for Death from Invasive Pneumococcal Disease, Europe, 2010 - Volume 21, Number 3—March 2015 - Emerging Infectious Disease journal - CDC

full-text ►

Ahead of Print -Risk Factors for Death from Invasive Pneumococcal Disease, Europe, 2010 - Volume 21, Number 3—March 2015 - Emerging Infectious Disease journal - CDC

CDC. Centers for Disease Control and Prevention. CDC 24/7: Saving Lives. Protecting People.

Volume 21, Number 3—March 2015


Risk Factors for Death from Invasive Pneumococcal Disease, Europe, 2010

Adoración Navarro-TornéComments to Author , Joana Gomes Dias, Frantiska Hruba, Pier Luigi Lopalco, Lucia Pastore-Celentano, Andrew J. Amato Gauci, and Invasive Pneumococcal Disease Study Group
Author affiliations: Universidad Autónoma de Barcelona, Barcelona, Spain (A. Navarro-Torné)European Centre for Disease Prevention and Control, Stockholm, Sweden (A. Navarro-Torné, J. Gomes Dias, F. Hruba, P.L. Lopalco, L. Pastore-Celentano, A.J. Amato Gauci)


We studied the possible association between patient age and sex, clinical presentation, Streptococcus pneumoniae serotype, antimicrobial resistance, and death in invasive pneumococcal disease cases reported by 17 European countries during 2010. The study sample comprised 2,921 patients, of whom 56.8% were men and 38.2% were >65 years of age. Meningitis occurred in 18.5% of cases. Death was reported in 264 (9.0%) cases. Older age, meningitis, and nonsusceptibility to penicillin were significantly associated with death. Non–pneumococcal conjugate vaccine (PCV) serotypes among children <5 years of age and 7-valent PCV serotypes among persons 5–64 years of age were associated with increased risk for death; among adults >65 years of age, risk did not differ by serotype. These findings highlight differences in case-fatality rates between serotypes and age; thus, continued epidemiologic surveillance across all ages is crucial to monitor the long-term effects of PCVs.
Streptococcus pneumoniae causes severe invasive disease that results in considerable illness and death. The incidence of invasive pneumococcal disease (IPD) is higher during the early years of life and among elderly persons (1). Geographic and ethnic differences also exist (1,2). Environmental factors (i.e., ambient temperature, humidity, and air pollution) affect IPD incidence (3,4). IPD has also been related to recent respiratory viral infection (4).
The ability of the different S. pneumoniae serotypes to cause disease has been related to serotype-specific characteristics and the molecular size of the capsular polysaccharide and chemical composition, among other factors (5). Therefore, it seems plausible that different serotypes exhibit different virulence and propensity to cause certain clinical presentation (5).
Brueggemann et al. studied the invasive disease potential of different S. pneumoniae serotypes (6). They concluded that so-called “highly invasive” serotypes (including 4, 1, 14, 18C, and 7F), convey a higher risk for invasive disease than do the “low invasive” serotypes (including 3, 15B/C, and 6B), which are more frequently isolated as colonizers (7). Furthermore, serotype distribution varies with patient age, both in disease and in nasopharyngeal colonization (2,810). However, evidence exists that pneumococcal invasiveness does not necessarily mean lethality (7). Low invasive serotypes usually account for higher case-fatality rates (CFRs).
The availability of 7-valent, 10-valent, and 13-valent pneumococcal conjugate vaccines (PCV7, PCV10, and PCV13, respectively) and their introduction as part of national immunization schedules have contributed to reducing illnesses and death from IPD (1012). Nevertheless, the subsequent replacement of vaccine serotypes by nonvaccine serotypes is an accepted and global phenomenon (13,14).
The incidence of drug- and multidrug-resistant S. pneumoniae strains is increasing worldwide (15). Antimicrobial use and abuse is a main driver for the emergence of antimicrobial resistance in respiratory pathogens. Persons who carry (nasopharyngeal colonization), and hence share the potential to transmit resistant pneumococci, also are more susceptible to IPD caused by resistant strains (16).
Monitoring antimicrobial resistance trends and serotype distribution is paramount because this information is essential in helping to determine risk factors and optimizing the appropriate clinical management of cases and public health interventions. We studied the possible association between age, sex, serotype, clinical presentation, antimicrobial resistance, and death among persons reported to have IPD in European countries during 2010.

Dr. Navarro-Torné is an expert in vaccine preventable diseases at the European Centre for Disease Prevention and Control. Her primary research interest is surveillance of vaccine preventable diseases, particularly on IPD and pertussis.


Members of the Invasive Pneumococcal Disease Study Group who contributed data this article: Martine Sabbe, Antoaneta Detcheva, Teodora Georgieva, Despo Pieridou Bagatzouni,Pavla Křížová, Palle Valentiner-Branth, Asunción Fenoll, Anni Virolainen-Julkunen,Theano Georgakopoulou, Georgina Tzanakaki, Márta Melles, Imelda Vickers, Suzanne Cotter, Hilary Humphreys, Karl G. Kristinsson, Maria Grazia Caporali, Fortunato Paolo D’Ancona, Stefania Iannazzo, Annalisa Pantosti, Jelena Galajeva, Paul Caruana, Jackie Maistre Melillo, Tanya Melillo Fenech, Hester De Melker, Mirjam Knol, Arie Van Der Ende, Martin Steinbakk, Didrik F Vestrheim,Waleria Hryniewicz, Alicja Kuch, Iwona Paradowska-Stankiewicz, Anna Skoczynska, Marina Pana, Birgitta Henriques-Normak, Alenka Kraigher, Maja Sočan, Helena Hupkova, Eisin MacDonald, Mary P.E. Slack, Pauline A. Waight.


  1. Lynch JPZhanel GGStreptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance and impact of vaccines. Curr Opin Pulm Med2010;16:21725 .PubMed
  2. Scott JAHall AJDagan RDixon JMSEykyn SJFenoll ASerogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex and geography in 7000 episodes of invasive disease. Clin Infect Dis1996;22:97381DOIPubMed
  3. Weinberger DMGrant LRSteiner CAWeatherholtz RSantosham MViboud CSeasonal drivers of pneumococcal disease incidence: impact of bacterial carriage and viral activity. Clin Infect Dis2014;58:18894DOIPubMed
  4. Launes CFernandez de Sevilla MSelva LGarcia Garcia JJPallares RMuñoz-Almagro CViral co-infection in children less than five years old with invasive pneumococcal disease. Pediatr Infect Dis J2012;31:6503DOIPubMed
  5. Weinberger DMHarboe ZBSanders EAMNdiritu MKlugman KPRückinger SRisk of death from pneumococcal pneumonia is a stable serotype-associated property: a meta-analysis. Clin Infect Dis2010;51:6929DOIPubMed
  6. Brueggemann ABGriffiths DTMeats EPeto TCrook DWSpratt BGClonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis2003;187:142432DOIPubMed
  7. Pletz MWWelte TKlugman KPThe paradox in pneumococcal serotypes: highly invasive does not mean highly lethal. Eur Respir J2010;36:7123.DOIPubMed
  8. Johnson HLDeloria-Knoll MLevine OSStoszek SKFreimanis Hance LReithinger RSystematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med2010;7:e1000348DOIPubMed
  9. Jansen AGSCRodenburg GDvan der Ende Avan Alphen LVeenhoven RHSpanjaard LInvasive pneumococcal disease among adults: association among serotypes, disease characteristics, and outcome. Clin Infect Dis2009;49:e239DOIPubMed
  10. Hausdorff WPFeikin DRKlugman KPEpidemiological differences among pneumococcal serotypes. Lancet Infect Dis2005;5:8393.DOIPubMed
  11. Miller EAndrews NJWaight PASlack MPGeorge RCEffectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine.Vaccine2011;29:912731DOIPubMed
  12. Palmu AAJokinen JNieminen HBorys DNieminen HRuokokoski EEffectiveness of the ten-valent pneumococcal Haemophilus influenzaeprotein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomized trial. Lancet2013;381:21422.DOIPubMed
  13. Weinberger DMMalley RLipsitch MSerotype replacement in disease after pneumococcal vaccination. Lancet2011;378:196273.DOIPubMed
  14. Weil-Olivier Cvan der Linden Mde Schutter IDagan RMantovani LPrevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect Dis2012;12:207DOIPubMed
  15. Reinert RRThe antimicrobial resistance profile of Streptococcus pneumoniae. Clin Microbiol Infect2009;15(Suppl 3):711DOIPubMed
  16. Dagan RBarkai GLeibovitz EDreifuss EGreenerg DWill reduction of antibiotic use reduce antibiotic resistance? The pneumococcus paradigm.Pediatr Infect Dis J2006;25:9816DOIPubMed
  17. European Antimicrobial Resistance Surveillance Network (EARS-Net). Antimicrobial resistance interactive database (EARS-Net) [cited 2014 Mar 2].http://www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/database.aspx
  18. European Centre for Disease Prevention and Control. Surveillance of invasive pneumococcal disease in Europe, 2010 [cited 2014 Mar 3].http://www.ecdc.europa.eu/en/publications/publications/invasive-pneumoccocal-disease-surveillance-2010.pdf
  19. Luján MGallego MBelmont YFontanals DVallés JLisboa TInfluence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia. Eur Respir J2010;36:10739DOIPubMed
  20. Martens PWorm SWLundgren BKonradsen HBBenfield TSerotype-specific mortality from invasive Streptococcus pneumoniae disease revisited. BMC Infect Dis2004;4:21DOIPubMed
  21. Yu VLChiou CCCFeldman COrtqvist ARello JMorris AJAn international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis2003;37:2307DOIPubMed
  22. Regev-Yochay GRahav GRiesenberg KWiener-Well YStrahilevitz JStein MInitial effects of the national PCV7 childhood immunization program on adult invasive pneumococcal disease. PLoS ONE2014;9:e88406DOIPubMed
  23. Simell BLahdenkari MReunanen AKäyhty HVäkeväinen MEffects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins. Clin Vaccine Immunol2008;15:13917DOIPubMed
  24. European Centre for Disease Prevention and Control. Vaccine schedule. Recommended immunisations for pneumococcal disease [cited 2014 Apr 7].http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx
  25. Harboe ZBThomsen RWRiis AValentiner-Branth PChristensen JJLambertsen LPneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med2009;6:e1000081DOIPubMed
  26. Vallès XMarcos APinart MPiñer RMarco FMensa JMHospitalized community-acquired pneumonia due to Streptococcus pneumoniae. Has resistance to antibiotics decreased? Chest2006;130:8006DOIPubMed
  27. Roed CEngsig FNOmland LHSkinhoj PObel NLong-term mortality in patients diagnosed with pneumococcal meningitis: a Danish nationwide cohort. Am J Epidemiol2010;172:30917DOIPubMed
  28. Rückinger Svon Kries RSiedler Avan der Linden MAssociation of serotype of Streptococcus pneumoniae with risk of severe and fatal outcome.Pediatr Infect Dis J2009;28:11822DOIPubMed
  29. Ladhani SNSlack MPEAndrews NJWaight PABorrow RMiller EInvasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales. Emerg Infect Dis2013;19:618DOIPubMed
  30. Pichon BLadhani SNSlack MPESegonds-Pichon AAndrews NJWaight PAChanges in molecular epidemiology of Streptococcus pneumoniaecausing meningitis following introduction of pneumococcal conjugate vaccination in England and Wales. J Clin Microbiol2013;51:8207.DOIPubMed
  31. Li YWeinberger DMThompson CMTrzciński KLipsitch MSurface charge of Streptococcus pneumoniae predicts serotype distribution. Infect Immun2013;81:451924DOIPubMed
  32. van Hoek AJAndrews NWaight PAGeorge RMiller EEffect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PLoS ONE2012;7:e39150DOIPubMed
  33. Myint TTHMadhava HBalmer PChristopoulou DAttal SMenegas DThe impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther2013;30:12751DOIPubMed
  34. Sjöström KSpindler CÖrtqvist AKalin MSandgren AKühlmann-Berenzon SClonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis2006;42:4519DOIPubMed
  35. Fenoll AAguilar LGiménez MJVicioso MDRobledo OGranizo JJSusceptibility of recently collected Spanish pneumococci nonsusceptible to oral penicillin from serotypes not included in the 7-valent conjugate vaccine. Antimicrob Agents Chemother2010;54:26968DOIPubMed
  36. Gouveia ELReis JNFlannery BCordeiro SMLima JBTPinheiro RMClinical outcome of pneumococcal meningitis during the emergence of penicillin-resistant Streptococcus pneumoniae: an observational study. BMC Infect Dis2011;11:323DOIPubMed
  37. Song JSChoe PGSong KHPark WBPark SWKim HBRisk factors for 30-day mortality in adult patients with pneumococcal bacteraemia, and the impact of antimicrobial resistance on clinical outcomes. Epidemiol Infect2012;140:126776DOIPubMed
  38. Feldman CAnderson RABacteremic pneumococcal pneumonia: current therapeutic options. Drugs2011;71:13153DOIPubMed
  39. Vila-Corcoles AOchoa-Gondar OPreventing pneumococcal disease in the elderly. Recent advances in vaccines and implications for clinical practice. Drugs Aging2013;30:26376DOIPubMed
  40. Miyaji ENSarno Oliveira MLCarvalho ELee Ho PSerotype-independent pneumococcal vaccines. Cell Mol Life Sci2013;70:330326 and.DOIPubMed



Suggested citation for this article: Navarro-Torné A, Gomes Dias J, Hruba F, Lopalco PL, Pastore-Celentano L, Amato Gauci AJ, et al. Risk factors for death from invasive pneumococcal disease, Europe, 2010. Emerg Infect Dis [Internet]. 2015 Mar [date cited]. http://dx.doi.org/10.3201/eid2103.140634
DOI: 10.3201/eid2103.140634
1Members of the Invasive Pneumococcal Disease Study Group who contributed data are listed at the end of this article.

No hay comentarios:

Publicar un comentario